Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on March 13, 2006
Japanese Journal of Clinical Oncology 2006 36(4):245-248; doi:10.1093/jjco/hyl003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
36/4/245    most recent
hyl003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Maruyama, R.
Right arrow Articles by Ichinose, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maruyama, R.
Right arrow Articles by Ichinose, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2006 Foundation for Promotion of Cancer Research

Case Report

Triplet Chemotherapy for Malignant Pericardial Mesothelioma: A Case Report

Riichiroh Maruyama1, Maki Sakai1, Tomomi Nakamura1, Ryuichi Suemitsu1, Tatsuro Okamoto1, Hiroshi Wataya1, Kenichi Nishiyama2, Toshiaki Kamei3 and Yukito Ichinose1

1 Department of Thoracic Oncology, 2 Pathology, Kyushu Cancer Center, Fukuoka and 3 Division of Pathology, Yamaguchi Prefectural Grand Medical Center, Yamaguchi, Japan

For reprints and all correspondence: Riichiroh Maruyama, Department of Thoracic Oncology, Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka 811-1395, Japan. E-mail: rmaruyama{at}nk-cc.go.jp

Received October 17, 2005; accepted December 27, 2005

Malignant pericardial mesothelioma (MPM) is a relatively rare neoplasm in Japan, and no standard treatment regimens have been established for this disease. A 47-year-old woman with MPM presenting with cardiac tamponade was treated using four cycles of chemotherapy consisting of cisplatin (CDDP) 40 mg/m2, gemcitabine (GEM) 800 mg/m2 and vinorelbine (VNR) 20 mg/m2 on days 1 and 8 every 4 weeks after pericardial drainage alone. The diagnosis of MPM was confirmed by an immunohistochemical procedure using either positive or negative markers of malignant mesothelioma in addition to conventional cytological examinations using pericardial effusion. The patient experienced no severe non-hematological or hematological toxicities except for grade 3 neutropenia. The patient has returned to her usual activities and has remained well for 24 months after the last chemotherapy without any evidence of disease progression.

Key Words: malignant pericardial mesothelioma • triplet chemotherapy • long-term survival


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur. J. Cardiothorac. Surg.Home page
G. R. Small, M. Nicolson, K. Buchan, and P. Broadhurst
Pericardial malignant mesothelioma: a latent complication of radiotherapy?
Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 745 - 747.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Castagneto, M. Botta, E. Aitini, F. Spigno, D. Degiovanni, O. Alabiso, M. Serra, A. Muzio, R. Carbone, R. Buosi, et al.
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)
Ann. Onc., February 1, 2008; 19(2): 370 - 373.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.